Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 168

The DOI matches its Crossref record.

A pilot study of rituximab in patients with recurrent, classic Hodgkin disease

Open access
Younes, Anas, Romaguera, Jorge, Hagemeister, Frederick, McLaughlin, Peter, Rodriguez, Maria Alma, Fiumara, Paolo, Goy, Andre, Jeha, Sima, Manning, John T., Jones, Dan, Abruzzo, Lynne V., Medeiros, L. Jeffrey · 2003 · Cancer

Abstract

BACKGROUND: To explore the potential role of infiltrating benign B cells in classic Hodgkin disease (HD) lesions in supporting the survival of malignant Hodgkin and Reed–Sternberg (H/RS) cells, the authors initiated a pilot study of rituximab. Rituximab is used to primarily deplete normal B cells from HD lesions. METHODS: Patients with recurrent, classic HD who had received a minimum of two prior treatment regimens, regardless of whether H/RS cells expressed CD20, were treated with 6 weekly doses of 375 mg/m 2 rituximab to selectively deplete infiltrating benign B cells. Objective tumor response was determined 3 weeks after completion of the last dose of rituximab and every 3 months thereafter. Serum samples were collected from patients before they started rituximab therapy and 3 weeks after the final course of rituximab. Serum cytokine levels of interleukin 6 (IL‐6), IL‐10, IL‐12, IL‐13, and interferon γ were determined using commercially available enzyme‐linked immunosorbent assay kits. RESULTS: Twenty‐two patients with nodular sclerosis histology were evaluable for treatment response. Five patients (22%) achieved partial or complete remission that lasted for a median of 7.8 months (range, 3.3–14.9 months). Remissions were observed in patients only at lymph node and splenic sites, but not at extranodal sites, and were irrespective of CD20 expression by H/RS cells. Furthermore, systemic (B) symptoms resolved in six of seven patients after therapy. In two patients, partial remissions were associated with a decline in serum IL‐6 levels. CONCLUSIONS: The current data suggest that rituximab therapy in patients with recurrent, classic HD can alter serum IL‐6 cytokine levels, can improve B symptoms, and may result in clinical remissions. Cancer 2003;98:310–4. © 2003 American Cancer Society. DOI 10.1002/cncr.11511

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.11511

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 168

Metadata

Authors
Younes, A., Romaguera, J., Hagemeister, F., McLaughlin, P., Rodriguez, M. A., Fiumara, P., Goy, A., Jeha, S., Manning, J. T., Jones, D., Abruzzo, L. V., & Medeiros, L. J.
Venue
Cancer
Publisher
Wiley
Published
2003-07-02
Volume
98
Issue
2
Pages
310-314
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1970129186
Cited by
168
References
0
FWCI
2.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. https://app.cochat.ai/papers/10.1002/cncr.11511
The paper
Younes, A., Romaguera, J., Hagemeister, F., McLaughlin, P., Rodriguez, M. A., Fiumara, P., Goy, A., Jeha, S., Manning, J. T., Jones, D., Abruzzo, L. V., & Medeiros, L. J. (2003). A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. https://doi.org/10.1002/cncr.11511

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.